Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
Net Income Growth Recovery in ProgressRecovering
Percentile Rank56
3Y CAGR-34.3%
5Y CAGR-10.1%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
-34.3%/yr
Quarterly compound
5Y CAGR
-10.1%/yr
Recent deceleration
Percentile
P56
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 9.74% |
| Q3 2025 | -18.09% |
| Q2 2025 | 13.25% |
| Q1 2025 | 7.10% |
| Q4 2024 | 6.16% |
| Q3 2024 | -18.89% |
| Q2 2024 | -2.17% |
| Q1 2024 | 38.35% |
| Q4 2023 | -22.22% |
| Q3 2023 | 0.59% |
| Q2 2023 | 8.28% |
| Q1 2023 | 18.05% |
| Q4 2022 | 34.34% |
| Q3 2022 | 15.12% |
| Q2 2022 | -6.52% |
| Q1 2022 | 5.75% |
| Q4 2021 | 16.00% |
| Q3 2021 | -21.05% |
| Q2 2021 | -12.04% |
| Q1 2021 | 17.26% |
| Q4 2020 | 16.58% |
| Q3 2020 | 14.49% |
| Q2 2020 | -8.00% |
| Q1 2020 | 60.04% |
| Q4 2019 | -31.69% |
| Q3 2019 | -1.47% |
| Q2 2019 | -8.14% |
| Q1 2019 | 60.88% |
| Q4 2018 | 40512.93% |
| Q3 2018 | -99.75% |
| Q2 2018 | -18.77% |
| Q1 2018 | 222.75% |
| Q4 2017 | -64.98% |
| Q3 2017 | -13.50% |
| Q2 2017 | -23.63% |
| Q1 2017 | 50.25% |
| Q4 2016 | 9.81% |
| Q3 2016 | -38.28% |
| Q2 2016 | 20.89% |
| Q1 2016 | 44.07% |